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Background
he randomized controlled trial (RCT) has long
been recognized as the most robust technique for eval-
uating the effects of mental health care interventions.
1
Sometimes these trials are impossible, sometimes uneth-
ical, and sometimes impractical. The first RCT was the
1948 Medical Research Council Streptomycin Trial.
2 In
the austere times of bankrupt, post-war England, just as
the National Health Service was being established, it was
suggested that a new drug would be of value for treat-
ment of tuberculosis. The only equitable way to distrib-
ute this scarce resource was through randomization and
then, by the establishment of good evidence, to encour-
age those funding health care to support its use. There
are many interesting and important examples preceding
this date,
3 but this landmark and courageous trial radi-
cally changed the pathway of evaluation of medical
treatments.
Mental health has a fine tradition of using trials to eval-
uate treatments.
4The MRC Streptomycin trial coincided
with the discovery of psychoactive compounds that were
potentially therapeutic, as well as an increasing push
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In the pragmatic-explanatory continuum, a randomized
controlled trial (RCT) can at one extreme investigate
whether a treatment could work in ideal circumstances
(explanatory), or at the other extreme, whether it would
work in everyday practice (pragmatic). How explanatory
or pragmatic a study is can have implications for clini-
cians, policy makers, patients, researchers, funding bod-
ies, and the public. There is an increasing need for stud-
ies to be open and pragmatic; however, explanatory
trials are also needed. The previously developed
Pragmatic-explanatory continuum indicator summary
(PRECIS) was adapted into the Pragmascope tool to assist
mental health researchers in designing RCTs, taking the
pragmatic-explanatory continuum into account. Ten
mental health trial protocols were randomly chosen and
scored using the tool by three independent raters. Their
results were compared for consistency and the tool was
found to be reliable and practical. This preliminary work
suggests that evaluating different domains of an RCT at
the protocol level is useful, and suggests that using the
Pragmascope tool presented here might be a practical
way of doing this.
© 2011, LLS SAS Dialogues Clin Neurosci. 2011;13:209-215.
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sionals discovered, discussed, and, largely, embraced the
use of RCTs. Up to the advent of antipsychotic drugs
such as chlorpromazine, psychiatric care had been
likened to “little more than zoo keeping”
5 and, perhaps
because of that stinging criticism, those undertaking the
trials did not necessarily follow the path of that first
tuberculosis trial. Factors combined to largely direct
mental health trials along another route. There was the
yearning for rigorous science, collective subspecialty
insecurity, and also the needs of regulatory authorities.
Mental health trials drifted towards use of as rigorous
diagnoses as possible, rather rigid regimens of care and
use of fine-grained outcome measures that are not usu-
ally part of routine practice. This planted the RCT firmly
in the realm of researchers, and there it has stayed. The
needs of regulatory authorities did have to be met, but
there was less consideration of needs of clinicians and of
recipients of care and their families.
This was not at all unique to mental health, but it took
leaders in the fields of cancer care,
6 heart disease,
7 and
perinatal medicine
8 to recall and refine the techniques
of generous inclusion, simple treatment, and routine data
collection that underpinned the MRC trial of 1948.
Many examples now exist in these areas of RCTs where
entry criteria are broad and encompass as many relevant
people as possible, the treatment packages are those that
would be given in everyday care, and outcomes are
essentially routinely recorded data. Examples of such
open work were rare in mental health until relatively
recently. The description of “pragmatic” or “practical” is
increasingly employed of trials in psychiatry or psychol-
ogy but there are clearly different interpretations of
what this really means. 
A recent series of papers has highlighted the problems
in interpretation of the explanatory/pragmatic domains
in trials and presented some practical solutions.
9 It is not
a simple continuum from explanatory through to prag-
matic. There are many elements of design that should be
considered to allow a judgment to take place about
whether a randomized trial is investigating whether, in
ideal circumstances, a treatment could work (explana-
tory) or, at the other extreme, whether this accessible
treatment would work in everyday practice (pragmatic).
This is not a purely academic exercise. There are good
reasons to make these judgments. To use one example,
funders, on receiving a proposal, may wish to consider
whether the proposed trial fits with the ethos in which
that support was proffered. For example one funding
body may be interested in discovering potentially new
treatments. In this instance, explanatory studies, under-
taken in very rigorous circumstances with fine measures
of outcome to highlight any—even modest—effects,
may be best. On the other hand, another funder, using
public money, may wish to consider whether the study
is likely to produce evidence of practical importance
regarding accessible treatments relevant to the major-
ity of people suffering with the condition in that com-
munity.
10 Here a much more pragmatic study would be
desired. How explanatory or pragmatic a study (or a
group of studies) is has also obvious and direct impli-
cations for clinicians, policymakers, patients, and the
public. 
The main goal of this study is to adapt the instrument
described by Thorpe et al
9 (PRECIS) to assist
researchers in making those judgments in the protocol
stage of RCTs in mental health (the Pragmascope
tool). 
Methods
The Pragmascope tool
This tool is based on the ten domains described in the
development of the Pragmatic-explanatory continuum
indicator summary (PRECIS).
9 It can be used to assess
applicability of results from any given RCT, based on
what was planned at the protocol stage. 
Each included RCT protocol
11-19 was scored in ten
domains by three independent reviewers (GT, KSW,
CEA). The reviewers made a judgment and rated the
protocol from 1 (most explanatory) to 5 (most prag-
matic) by reading the details of the protocol. If the pro-
tocol did not contain any information on which to base
the decision, these domains were rated as zero. The aver-
age scores for each included protocol were placed on the
wheel diagram and the dots joined for visual clarity
(Figure 1). 
Selection of RCT protocols 
We searched the Cochrane Schizophrenia Group Trials
Register and Medline (November 2010) for references of
RCT protocols and chose a random sample of 10 proto-
cols dealing with schizophrenia, depression, post-trau-
matic stress disorders, and psychiatric rehabilitation.
11-19
Clinical research
210
PAGES_12_AG_1003_BA.qxd:DCNS#49  18/06/11  15:37  Page 210Scoring the Pragmascope tool
Three independent reviewers (GT, KSW, CEA) scored
each included RCT protocol. The overall score can be
from 0 to 50 and a diagram illustrating how open (prag-
matic) or restrictive (explanatory) the study is likely to
be was created using the average score of the three inde-
pendent reviewers.
Our initial interpretation of the scores was of 0 to 30 for
an explanatory study investigating whether the experi-
mental intervention will work in ideal circumstances and
a total score >35 for a more pragmatic study focusing
mostly on whether, in routine practice, an intervention
has a meaningful effect. A total score between 31 and 39
were interpreted as an interim where trial design bal-
ances pragmatic and explanatory domains. 
Data analysis
Mean and variance were calculated for each domain of
the Pragmascope tool for each included RCT protocol
using STATA (version 10). In addition, a weighted
kappa for the domains was calculated using R.
Results
Table I presents the average score of the three raters in
each one of the domains for each RCT protocols with a
judgment based on the scores.  Reliability among the
three independent raters was high (weighted Kappa =0.72
for categories 0-30, 31-39, 40-50) suggesting that this clus-
ter of judgments might be useful to highlight and quantify
important issues during the protocol stage of an RCT. 
We recognize that validity is a more problematic issue, as
this does depend on the rater’s perspective, but work is
ongoing involving raters from very different backgrounds.
In any case, we concur that consideration of these
domains is useful
9 and suggest that the Pragmascope is
one practical way of doing this. 
Discussion
The world of RCTs has changed remarkably in the last
10 years. Systematic reviewing of trials, now industrially
undertaken through initiatives like the Cochrane
Collaboration,
20 has highlighted issues with poor design
and inconsistent reporting. These systematic reviews are
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Figure 1. Examples of output. 
Reproduced from ref 9: Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A pragmatic-explanatory continuum indicator
summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62:464-475. Copyright ©2009 Elsevier
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dence that is difficult or impossible to apply in the real
world. For mental health, studies of increasing pragma-
tism are now being designed and undertaken.
21-23 Such
pragmatic, real-world, practical design can be dovetailed
within explanatory studies or sit independently. With
maintained systematic reviews guiding practice,
21 trans-
parent priority setting for research funding for evalua-
tive research,
3 and the push towards defining core out-
come measures of agreed relevance in trials,
24 a great
increase in pragmatic trial activity is likely. Of course
explanatory trials have an important place in the port-
folio of research, but the rigorously undertaken but
highly pragmatic trial will give us the opportunity to
learn much more about the real effects of the potent
treatments we give.  ❏
Acknowledgements: We would like to thank Dr K. Thorpe for consider-
ation of our rating tool, and Dr B. Park for help calculating Kappa.
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Domain ACHIEVE
14 CATIE
11 CCEST
17 DYD
18 ERP
16 FIAT
19 PTSD- Yoga
20 ROMT
15 SPCCD
13 TREC –SAVE
(Low) (Low) (Low) (Low) (Low) (High) (Moderate) (Moderate) (Low) (High) 
(unpublished)
Eligibility criteria 1 2 2 2 2 3 2 3 2 5
Flexibility of  2 3 3 3 1 4 2 3 3 4
intervention
Practitioner expertise  1 3 2 2 2 5 2 2 2 4
(intervention)
Practitioner expertise  4 3 4 2 5 5 5 5 5 5
(comparison)
Flexibility of comparison  3 3 3 3 5 5 5 5 4 5
intervention
Outcomes 3 2 3 3 2 4 4 3 2 4
Participant compliance 4 2 4 3 2 4 5 5 3 4
Practitioner adherence 3 2 3 3 2 4 5 4 3 5
Primary analysis of  1 2 1 3 5 4 4 4 5 4
outcomes
Follow-up intensity 1 2 3 5 2 4 2 2 2 5
Total Average score 23 25 29 28 27 43 34 34 28 45
Table I. Average score of three raters for each one of the domains of the  RCT protocol.
Appendix. The Pragmascope (Figures 2 and 3)
Explanation: This tool is based on ten domains described in the devel-
opment of the Pragmatic-explanatory continuum indicator summary
(PRECIS).
9 It can be used to assess applicability of results from any given
randomized controlled trial. 
Instructions: For each of the ten domains please make a judgement and
rate the protocol from 1 (most explanatory) to 5 (most pragmatic). Your
score should be based on a thorough reading of the protocol. If the pro-
tocol does not contain any information on which to base your decision
we advise a default score of zero. If you feel your scores require justi-
fication - please make comments in box provided. Mark score on rele-
vant part of the diagram and join the dots. 
Results: The scoring can give you an overall score (0-50) and a diagram
illustrating how open (pragmatic) or restrictive (explanatory) the study
is likely to be. 
Interpretation: Figure 1 (see main text) demonstrates an explanatory study
investigating whether the experimental intervention will work in ideal cir-
cumstances (total score 0-15) and a more pragmatic study focusing mostly
on whether, in routine practice, an intervention has a meaningful effect
(total score >35). A total score between 16 and 35 suggest an interim
where trail design balances pragmatic and explanatory domains. 
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1. Eligibility criteria
  ￿ Does the study population represent the people who will 
    really be treated with the experimental intervention?
  ￿ Think about restrictions to participation - such as a 
    pre-determined number of participants or any exclusion 
    criteria which make the trial less real-world. 
  ￿ Consider any selection bias toward high risk people or 
    those without co-morbidity.
  ￿ Trials open to the entire target population are more
    pragmatic, those which have exclusion criteria become 
    progressively less so as exclusions become more rigid.
Explanatory pragmatic
        0        1        2        3        4        5
2. Flexibility of experimental intervention
  ￿ Does application of the intervention allow for variation 
    and adaptability which exists in everyday life?
  ￿ Think about rigidity of protocol application and strict, 
    extensive or complex instructions - these make a study less 
   pragmatic.
  ￿ Less pragmatic still are trials which closely monitor 
    application of intervention and make exclusions based on 
   this.
  ￿ If creativity is allowed or encouraged in applying the 
    intervention and/or it is tailored to fit the individual - this 
    is more representative of real life and more pragmatic. 
Explanatory pragmatic
        0        1        2        3        4        5
3. Practitioner expertise 
    - for experimental intervention
  ￿ Can the experimental intervention be carried out by 
    people ordinarily involved with the care of participants?
  ￿ Less pragmatic interventions require higher levels of 
    practitioner expertise – this can mean staff education or 
    training (intensity is important) or bringing in others not 
    normally involved in the care of participants.
  ￿ Sometimes the intervention requires involvement of an 
    external expert - particularly non-pragmatic. 
Explanatory pragmatic
        0        1        2        3        4        5
4. Practitioner expertise 
    - for comparison intervention
  ￿ Can the comparison be carried out by people ordinarily 
    involved with the care of participants?
  ￿ Less pragmatic interventions require higher levels of 
    practitioner expertise – this can mean staff education or 
    training (intensity is important) or bringing in others not 
    normally involved in the care of participants.
  ￿ Sometimes the intervention requires involvement of an 
    external expert - particularly non-pragmatic. 
Explanatory pragmatic
        0        1        2        3        4        5
5. Flexibility of comparison
  ￿ Is the intervention being compared with what is currently 
    happening in everyday practice? The level of pragmatism is
     reduced by comparing the experimental intervention to 
    other structured or regulated comparisons. 
  ￿ The ideal pragmatic comparison is unregulated treatment 
   as  usual.
  ￿ The more a comparison diverges from this by introducing 
    regulation, instruction or monitoring - the more 
    explanatory the trial becomes.
Explanatory pragmatic
        0        1        2        3        4        5
6. Outcomes
  ￿ Are outcomes important to the health/needs of 
    participants (pragmatic) or the needs/profits of the 
   researcher  (explanatory)?
  ￿ How complex is the measurement of outcomes?
  ￿ How much does measurement of outcome require input 
   from  participants? 
  ￿ More pragmatic trials will look at outcomes in the long 
    term and no specific training will be required for 
   measurement. 
  ￿ Pragmatism should also avoid the need for central 
    adjudication of outcome measurement.
    The outcome should be positive for the participant.
Explanatory pragmatic
        0        1        2        3        4        5
7. Participant compliance
  ￿ In real life compliance with treatment is highly variable, 
    does this trial falsely eliminate non-compliance by 
    monitoring or by excluding those who falter in 
   compliance?
  ￿ Pragmatic trials accept that non-compliance is a fact of life 
    and therefore avoid monitoring, or trying to improve 
   compliance.
  ￿ Ideally pragmatic trials should avoid measuring compliance 
    altogether since any information obtained could be used in 
    future trials to falsely improve compliance.
Explanatory pragmatic
        0        1        2        3        4        5
8. Practitioner adherence
  ￿ Does this study regulate adherence to treatment to a 
    degree which would not be replicated in real life?
  ￿ Pragmatic trials should avoid monitoring practitioner 
    adherence to the study protocol, explanatory trials would 
    try to identify practitioners with poor compliance and 
    possibly eliminate their data from the study.
  ￿ Between these two extremes trials which try to improve 
    adherence are less pragmatic and those which allow for 
    individual creativity and flexibility are more so.
Explanatory pragmatic
        0        1        2        3        4        5
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9. Analysis of outcomes
  ￿ Have they excluded any data? Exclusion of data often shifts 
    a trial away from pragmatism because it has the effect of 
    making the trial an ideal situation rather than a real one. 
  ￿ For optimum pragmatism the analysis should avoid looking 
    at subgroups or excluding data because of practitioner 
    adherence, participant compliance or other factors.
  ￿ More data exclusion = less pragmatic.
Explanatory pragmatic
        0        1        2        3        4        5
10. Follow-up intensity
  ￿ Intense follow-up is not a realistic scenario. The pragmatic 
    approach to follow-up is covert and would occur during 
    usual care preferably with as little disruption to the 
    participant’s normal routine as possible. 
  ￿ Follow up should be long term.
  ￿ More explanatory follow-up measures may include: 
    pre-specified appointments for the collection of data, short 
    term follow up looking for a specific outcome, coercion or 
    encouragement to attend follow-up and the collection of 
    unusually large amounts of data not directly relevant to 
   the  participant.
Explanatory pragmatic
        0        1        2        3        4        5
Ensayos pragmáticos versus explicativos:
Pragmascope, el instrumento que 
ayudar a medir las diferencias en los 
protocolos de ensayos controlados 
randomizados de salud mental
En el continuo pragmático-explicativo, un ensayo
controlado randomizado (ECR) puede investigar por
una parte si un tratamiento podría funcionar en cir-
cunstancias ideales (explicativas) y por otra si podría
funcionar en la práctica diaria (pragmático). Cuan
explicativo o pragmático sea un estudio, puede
tener repercusiones para los clínicos, los políticos, los
pacientes, los investigadores, los organismos de
financiamiento y el público. Hay una necesidad cre-
ciente de que los estudios sean abiertos y pragmáti-
cos; sin embargo, también son necesarios los ensa-
yos explicativos. PRECIS, el resumen del indicador del
continuo pragmático-explicativo que se había desa-
rrollado con anterioridad, se adaptó al instrumento
Pragmascope para ayudar a los investigadores de
salud mental en los diseños de ECR, tomando en
consideración el continuo pragmático-explicativo.
Se eligieron randomizadamente diez protocolos de
ensayos de salud mental y se les asignó puntaje
mediante el instrumento por tres evaluadores inde-
pendientes. Sus resultados se compararon en cuanto
a consistencia y se encontró que el instrumento fue
confiable y práctico. Este trabajo preliminar sugiere
que es útil la evaluación de diferentes aspectos de
un ECR a nivel del protocolo y propone que el
empleo del instrumento Pragmascope presentado
aquí sería una forma práctica de hacerlo. 
Études pragmatiques versus explicatives :
l’outil Pragmascope de mesure pour mesurer
les différences dans les protocoles d’études
contrôlées randomisées sur la santé mentale 
Dans le continuum pragmatique-explicatif, une
étude contrôlée randomisée (ECR) peut d’un côté
analyser l’efficacité d’un traitement en circonstances
idéales (explicatives) ou d’un autre côté son effica-
cité dans la pratique quotidienne (pragmatique).
Qu’une étude soit explicative ou pragmatique, elle
peut avoir des implications pour les médecins, les
responsables politiques, les patients, les chercheurs,
les organismes de financement et le public. Les
études doivent de plus en plus être ouvertes et prag-
matiques, mais les études explicatives sont aussi
nécessaires. L’indicateur de continuum pragmatique
- explicatif PRECIS (Pragmatic-explanatory conti-
nuum indicator summary) développé antérieure-
ment a été adapté sous forme de l’outil PRAGMA-
SCOPE pour aider les chercheurs en santé mentale à
concevoir des ECR, en prenant en compte ledit
continuum. Dix protocoles d’études en santé men-
tale ont été choisis et cotés au hasard grâce à l’ou-
til, par trois évaluateurs indépendants. Leurs résul-
tats ont été comparés pour évaluer leur cohérence
et l’outil s’est avéré fiable et pratique. Ce travail pré-
liminaire  suggère que l’évaluation des différents
domaines des ECR au niveau du protocole est utile
et que l’utilisation du PRAGMASCOPE présenté ici
pourrait être un moyen pratique de le faire. 
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